What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?

Hormones

Volumn 11, Issue 4, 2012, Pages 477-482

  Phillips, Jana ^a   East, Honey E ^a   French, Sarah E ^a   Melcescu, Eugen ^a   Hamilton, Robert D ^a   Nicholas, William C ^a   Fratkin, Jonathan F ^a   Parent, Andrew D ^a   Luzardo, Gustavo ^a   Koch, Christian A ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cabergoline; Pituitary carcinoma; Prolactin; Temozolomide

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DESMOPRESSIN; DEXAMETHASONE; ETIRACETAM; HISTONE H3; HYDROCORTISONE; KI 67 ANTIGEN; LEVOTHYROXINE; PROLACTIN; PROTEIN P53; TEMOZOLOMIDE; TESTOSTERONE;

ADULT; ARTICLE; BLINDNESS; BRAIN VASOSPASM; CANCER INVASION; CASE REPORT; CAVERNOUS SINUS; CRANIOTOMY; DIABETES INSIPIDUS; DRUG DOSE INCREASE; DYSPHAGIA; ENTERIC FEEDING; FATIGUE; FOLLOW UP; GAMMA KNIFE; HEADACHE; HEMIPLEGIA; HISTOPATHOLOGY; HOSPICE CARE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTUBATION; LIBIDO DISORDER; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; OPTIC CHIASM; ORBIT; PROLACTINOMA; PROTON THERAPY; SELLA TURCICA; TEMPORAL LOBE; TRACHEOSTOMY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TROCHLEAR NERVE PALSY; TUMOR GROWTH; TUMOR REGRESSION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 84871998498     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1380     Document Type: Article

References (25)

1. Heaney AP, 2011 Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96: 3649-3660.
2. Dudziak K, Honegger J, Bornemann A, et al, 2011 Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course-case report and review of the literature. J Clin Endocrinol Metab 96: 2665-2669.
3. Mete O, Ezzat S, Asa SL, 2012 Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49: R69-78.
4. Singer J, Koch CA, Kassahun W, et al, 2011 A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nat Rev Endocrinol 7: 749-755.
5. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds), 2004 World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press.
6. Turner HE, Wass JA, 1999 Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1: 147-151.
7. Galland F, Lacroix L, Saulnier P, et al, 2010 Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17: 361-371.
8. Boikos SA, Stratakis CA, 2007 Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum Mol Genet 16: R80-87.
9. Stratakis CA, Tichomirowa MA, Boikos S, et al, 2010 The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 78: 457-463.
10. Ahmad S, Aaltonen LA, Georgitsi M, et al, 2007 Do single nucleotide polymorphisms in the AIP gene and MEN 1 gene predispose individuals to the development of familial isolated pituitary tumors ? Exp Clin Endocrinol 115: S35-36.
11. Glasker S, Vortmeyer AO, Lafferty AR, et al, 2011 Hereditary pituitary hyperplasia with infantile gigantism. J Clin Endocrinol Metab 96: E2078-2087.
12. Vortmeyer AO, Glasker S, Mehta GU, et al, 2012 Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metab 97: 2404-2413.
13. Gurlek A, Karavitaki N, Ansorge O, Wass JA, 2007 What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis, and genetics. Eur J Endocrinol 156: 143-153.
14. Molitch ME, 2008 The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 93: 4643-4645.
15. Byrne S, Karapetis C, Vrodos N, 2009 Novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16: 1694-1696.
16. Neff L, Weil M, Hedges TR, et al, 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81-86.
17. Miehle K, Tannapfel A, Lamesch P, et al, 2004 Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab 89: 3731-3736.
18. Koch CA, Mauro D, Walther MM, et al, 2002 Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13: 17-27.
19. Oh MC, Aghi MK, 2011 Dopamine agonist-resistant prolactinomas. J Neurosurg 114: 1369-1379.
20. Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M, 2011 Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14: 80-91.
21. Kovacs K, Horvath E, Syro LV, et al, 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38:185-189.
22. Bush ZM, Longtine JA, Cunningham T, et al, 2010 Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95: E280-290.
23. Raverot G, Sturm N, de Fraipont F, et al, 2010 Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592-4599.
24. Syro LV, Ortiz LD, Scheithauer BW, et al, 2011 Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117: 454-462.
25. Kars M, Roelfsema F, Romijn JA, Pereira AM, 2006 Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155: 523-534.